Patents by Inventor Bart KLEIN
Bart KLEIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240141336Abstract: RNA editing is achieved using oligonucleotide constructs comprising (i) a targeting portion specific for a target nucleic acid sequence to be edited and (ii) a recruiting portion capable of binding and recruiting a nucleic acid editing entity naturally present in the cell. The nucleic acid editing entity, such as ADAR, is redirected to a preselected target site by means of the targeting portion, thereby promoting editing of preselected nucleotide residues in a region of the target RNA which corresponds to the targeting portion.Type: ApplicationFiled: June 8, 2023Publication date: May 2, 2024Applicant: ProQR Therapeutics II B.V.Inventors: Bart KLEIN, Gerardus Johannes PLATENBURG
-
Publication number: 20240132890Abstract: The invention relates to nucleic acid molecules for pseudouridylation of a target uridine in a target RNA in a mammalian cell, wherein the nucleic acid molecule comprises a guide region capable of forming a partially double stranded nucleic acid complex with the target RNA comprising the target uridine, wherein the partially double stranded nucleic acid complex is capable of engaging a mammalian pseudouridylation enzyme, wherein the guide region assists in positioning the target uridine in the partially double stranded nucleic acid complex for it to be converted to a pseudouridine by the mammalian pseudouridylation enzyme.Type: ApplicationFiled: September 27, 2023Publication date: April 25, 2024Applicants: University of Rochester, ProQR Therapeutics II B.V.Inventors: Bart KLEIN, Janne Juha TURUNEN, Lenka VAN SINT FIET, Pedro Duarte Morais Fernandes Arantes DA SILVA, Julien Auguste Germain BOUDET, Yi-Tao YU, Hironori ADACHI, Meemanage De ZOYSA
-
Patent number: 11866702Abstract: The invention relates to nucleic acid molecules for pseudouridylation of a target uridine in a target RNA in a mammalian cell, wherein the nucleic acid molecule comprises a guide region capable of forming a partially double stranded nucleic acid complex with the target RNA comprising the target uridine, wherein the partially double stranded nucleic acid complex is capable of engaging a mammalian pseudouridylation enzyme, wherein the guide region assists in positioning the target uridine in the partially double stranded nucleic acid complex for it to be converted to a pseudouridine by the mammalian pseudouridylation enzyme.Type: GrantFiled: March 27, 2019Date of Patent: January 9, 2024Assignees: University of Rochester, ProQR Therapeutics II B.V.Inventors: Bart Klein, Janne Juha Turunen, Lenka Van Sint Fiet, Pedro Duarte Morais Fernandes Arantes Da Silva, Julien Auguste Germain Boudet, Yi-Tao Yu, Hironori Adachi, Meemanage De Zoysa
-
Patent number: 11851656Abstract: The invention relates to antisense oligonucleotides that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA sequence in a eukaryotic cell, wherein said oligonucleotide does not, in itself, form an intramolecular hairpin or stem-loop structure, and wherein said oligonucleotide comprises a non-complementary nucleotide in a position opposite to the nucleotide to be edited in the target RNA sequence.Type: GrantFiled: January 20, 2021Date of Patent: December 26, 2023Assignee: ProQR Therapeutics II B.V.Inventors: Janne Juha Turunen, Antti Aalto, Bart Klein, Lenka Van Sint Fiet, Julien Auguste Germain Boudet
-
Patent number: 11781134Abstract: RNA editing is achieved using oligonucleotide constructs comprising (i) a targeting portion specific for a target nucleic acid sequence to be edited and (ii) a recruiting portion capable of binding and recruiting a nucleic acid editing entity naturally present in the cell. The nucleic acid editing entity, such as ADAR, is redirected to a preselected target site by means of the targeting portion, thereby promoting editing of preselected nucleotide residues in a region of the target RNA which corresponds to the targeting portion.Type: GrantFiled: March 3, 2020Date of Patent: October 10, 2023Assignee: ProQR Therapeutics II B.V.Inventors: Bart Klein, Gerardus Johannes Platenburg
-
Publication number: 20230279392Abstract: The invention relates to antisense oligonucleotide that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA in a eukaryotic cell, wherein said oligonucleotide does not, in itself, form an intramolecular hairpin or stem-loop structure, and wherein said oligonucleotide comprises a cytidine (a non-complementary nucleotide) or a uridine in a position opposite to the target adenosine to be edited in the target RNA region.Type: ApplicationFiled: April 6, 2023Publication date: September 7, 2023Applicant: ProQR Therapeutics II B.V.Inventors: Janne Juha TURUNEN, Petra Geziena DE BRUIJN, Bart KLEIN, Roxana Simona REDIS, Lenka VAN SINT FIET
-
Patent number: 11649454Abstract: The invention relates to antisense oligonucleotides that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA in a eukaryotic cell, wherein said oligonucleotide does not, in itself, form an intramolecular hairpin or stem-loop structure, and wherein said oligonucleotide comprises a cytidine (a non-complementary nucleotide) or a uridine in a position opposite to the target adenosine to be edited in the target RNA region.Type: GrantFiled: March 26, 2021Date of Patent: May 16, 2023Assignee: ProQR Therapeutics II B.V.Inventors: Janne Juha Turunen, Petra Geziena De Bruijn, Bart Klein, Roxana Simona Redis, Lenka Van Sint Fiet
-
Publication number: 20220340900Abstract: The invention relates to single-stranded RNA editing antisense oligonucleotides (AONs) for binding to a target RNA molecule for deaminating a target nucleotide, preferably an adenosine, present in the target RNA molecule and recruiting, in a cell, preferably a human cell, an enzyme with nucleotide deamination activity, preferably an ADAR enzyme, to deaminate the target nucleotide in the target RNA molecule. The AONs carry at least one methylphosphonate-modified internucleosidic linkage on a position that would render the AON more stable in comparison to an AON not carrying that methylphosphonate modification at that position.Type: ApplicationFiled: April 2, 2020Publication date: October 27, 2022Inventors: Janne Juha Turunen, Bart Klein, Lenka Van Sint Fiet, Antti Aalto, Cherie Paige Kemmel, Tess Hoogeboom, Lisanne Alieda Van Wissen
-
Publication number: 20210340529Abstract: The invention relates to antisense oligonucleotides that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA in a eukaryotic cell, wherein said oligonucleotide does not, in itself, form an intramolecular hairpin or stem-loop structure, and wherein said oligonucleotide comprises a cytidine non-complementary, nucleotide) or a uridine in a position opposite to the target adenosine to be edited in the target RNA region.Type: ApplicationFiled: March 26, 2021Publication date: November 4, 2021Inventors: Janne Juha Turunen, Petra Geziena De Bruijn, Bart Klein, Roxana Simona Redis, Lenka Van Sint Fiet
-
Publication number: 20210238597Abstract: The invention relates to antisense oligonucleotides that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA sequence in a eukaryotic cell, wherein said oligonucleotide does not, in itself, form an intramolecular hairpin or stem-loop structure, and wherein said oligonucleotide comprises a non-complementary nucleotide in a position opposite to the nucleotide to be edited in the target RNA sequence.Type: ApplicationFiled: January 20, 2021Publication date: August 5, 2021Inventors: Janne Juha Turunen, Antti Aalto, Bart Klein, Lenka Van Sint Fiet, Julien Auguste Germain Boudet
-
Patent number: 10988763Abstract: The invention relates to antisense oligonucleotides that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA in a eukaryotic cell, wherein said oligonucleotide does not, in itself, form an intramolecular hairpin or stem-loop structure, and wherein said oligonucleotide comprises a cytidine (a non-complementary nucleotide) or a uridine in position opposite to the target adenosine to be edited in the target RNA region.Type: GrantFiled: June 22, 2017Date of Patent: April 27, 2021Assignee: PROQR THERAPEUTICS II B.V.Inventors: Janne Juha Turunen, Petra Geziena De Bruijn, Bart Klein, Roxana Simona Redis, Lenka Van Sint Fiet
-
Patent number: 10941402Abstract: The invention relates to antisense oligonucleotides that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA sequence in a eukaryotic cell, wherein said oligonucleotide does not, in itself, form an intramolecular hairpin or stem-loop structure, and wherein said oligonucleotide comprises a non-complementary nucleotide in a position opposite to the nucleotide to be edited in the target RNA sequence.Type: GrantFiled: August 31, 2017Date of Patent: March 9, 2021Assignee: PROQR THERAPEUTICS II B.V.Inventors: Janne Juha Turunen, Antti Aalto, Bart Klein, Lenka Van Sint Fiet, Julien Auguste Germain Boudet
-
Publication number: 20210010002Abstract: The invention relates to nucleic acid molecules for pseudouridylation of a target uridine in a target RNA in a mammalian cell, wherein the nucleic acid molecule comprises a guide region capable of forming a partially double stranded nucleic acid complex with the target RNA comprising the target uridine, wherein the partially double stranded nucleic acid complex is capable of engaging a mammalian pseudouridylation enzyme, wherein the guide region assists in positioning the target uridine in the partially double stranded nucleic acid complex for it to be converted to a pseudouridine by the mammalian pseudouridylation enzyme.Type: ApplicationFiled: March 27, 2019Publication date: January 14, 2021Inventors: Bart Klein, Janne Juha Turunen, Lenka Van Sint Fiet, Pedro Duarte Morais Fernandes Arantes Da Silva, Julien Auguste Germain Boudet, Yi-Tao Yu, Hironori Adachi, Meemanage De Zoysa
-
Publication number: 20200199586Abstract: RNA editing is achieved using oligonucleotide constructs comprising (i) a targeting portion specific for a target nucleic acid sequence to be edited and (ii) a recruiting portion capable of binding and recruiting a nucleic acid editing entity naturally present in the cell. The nucleic acid editing entity, such as ADAR, is redirected to a preselected target site by means of the targeting portion, thereby promoting editing of preselected nucleotide residues in a region of the target RNA which corresponds to the targeting portion.Type: ApplicationFiled: March 3, 2020Publication date: June 25, 2020Inventors: Bart Klein, Gerardus Johannes Platenburg
-
Patent number: 10676737Abstract: RNA editing is achieved using oligonucleotide constructs comprising (i) a targeting portion specific for a target nucleic acid sequence to be edited and (ii) a recruiting portion capable of binding and recruiting a nucleic acid editing entity naturally present in the cell. The nucleic acid editing entity, such as ADAR, is redirected to a preselected target site by means of the targeting portion, thereby promoting editing of preselected nucleotide residues in a region of the target RNA which corresponds to the targeting portion.Type: GrantFiled: December 17, 2015Date of Patent: June 9, 2020Assignee: ProQR Therapeutics II B.V.Inventors: Bart Klein, Gerardus Johannes Platenburg
-
Publication number: 20190330622Abstract: The invention relates to antisense oligonucleotides that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA in a eukaryotic cell, wherein said oligonucleotide does not, in itself, form an intramolecular hairpin or stem-loop structure, and wherein said oligonucleotide comprises a cytidine (a non-complementary nucleotide) or a uridine in position opposite to the target adenosine to be edited in the target RNA region.Type: ApplicationFiled: June 22, 2017Publication date: October 31, 2019Inventors: Janne Juha Turunen, Petra Geziena De Bruijn, Bart Klein, Roxana Simona Redis, Lenka Van Sint Fiet
-
Publication number: 20190218552Abstract: The invention relates to antisense oligonucleotides that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA sequence in a eukaryotic cell, wherein said oligonucleotide does not, in itself, form an intramolecular hairpin or stem-loop structure, and wherein said oligonucleotide comprises a non-complementary nucleotide in a position opposite to the nucleotide to be edited in the target RNA sequence.Type: ApplicationFiled: August 31, 2017Publication date: July 18, 2019Inventors: Janne Juha Turunen, Antti Aalto, Bart Klein, Lenka Van Sint Fiet, Julien Auguste Germain Boudet
-
Publication number: 20190040383Abstract: RNA editing is achieved using oligonucleotide constructs comprising (i) a targeting portion specific for a target nucleic acid sequence to be edited and (ii) a recruiting portion capable of binding and recruiting a nucleic acid editing entity naturally present in the cell. The nucleic acid editing entity, such as ADAR, is redirected to a preselected target site by means of the targeting portion, thereby promoting editing of preselected nucleotide residues in a region of the target RNA which corresponds to the targeting portion.Type: ApplicationFiled: December 17, 2015Publication date: February 7, 2019Inventors: Bart Klein, Gerardus Johannes Platenburg
-
Publication number: 20160228339Abstract: Mouth hygiene compositions that reduce VSC by changing the growth conditions in the oral cavity in favor of bacteria capable of anaerobic respiration. Anaerobic respiration is a form of respiration that involves electron acceptors other than oxygen. Examples of such alternative electron acceptors are sulfates, nitrates, sulfur and fumarate. A shift towards anaerobic respirational growth of the microflora in the oral cavity is brought about using an oral hygiene composition that is rich in nitrates. Such a composition considerably reduces the production of VSC compounds, especially hydrogen sulfide. Moreover, it has been established that by using these oral hygiene compositions, the overall diversity of the mouth flora is not diminished, but rather shifted from an halitotic (strictly anaerobically growing) bacterial population to a less halitotic one. The compositions are suitably used to treat and/or prevent halitosis in mammals.Type: ApplicationFiled: September 18, 2014Publication date: August 11, 2016Inventors: Willem CRIELAARD, Martijn BRUGMAN, Ronald Hendrik Pieter BRUS, Bart KLEIN